Q2 FY2026 · ended Jun 30, 2026 · Revenue $5.43M, -5.3% YoY · Filed Oct 20, 2026
Celularity Inc. (CELU) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $5.4 million and net income of $706,000. As of Jun 30, 2026 it held $586,000 in cash and investments and $27.1 million in total debt.
Revenue
$5.43M
-5.3% vs year-ago quarter
Net income
$706,000
+102.9% vs year-ago quarter
Operating cash flow
$-1.11M
-10.9% vs year-ago quarter
Free cash flow
$1.50M
+1143.8% vs prior quarter
EPS
$0.02
+102.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
32.45M
+21.6% vs year-ago quarter
Net cash
$-26.47M
Q2 FY2026
Operating margin
-264.3%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CELU (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Florham Park, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1752828
- Former names
- GX Acquisition Corp. (until Jul 19, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $5.4M | $3.8M | $4.1M | $5.3M | $5.7M |
| Operating income | -$4.2M | -$10.1M | -$22.1M | -$12.9M | -$15.9M |
| Net income | $706,000 | $874,000 | -$24.4M | -$23.1M | -$24.5M |
| Diluted EPS | $0.02 | $0.02 | -$0.86 | -$0.88 | -$1.02 |
| Operating cash flow | -$1.1M | $1.4M | -$5.1M | -$4.2M | -$999,000 |
| Total assets | $96.2M | $99.5M | $107.3M | $114.2M | $120.3M |
| Total liabilities | $131.7M | $134.7M | $145.4M | $134.3M | $145.8M |
| Stockholders' equity | -$35.5M | -$35.3M | -$38.1M | -$20.1M | -$25.5M |
| Cash and investments | $586,000 | $368,000 | $6.2M | $3.0M | $863,000 |
| Total debt | $27.1M | $27.0M | $60.7M | $62.5M | $33.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Oct 20, 2026 | Jun 30, 2026 |
| 10-K/A | Amended annual report | Oct 20, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 29, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Sep 29, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Officer or director change
|
Sep 28, 2026 | Sep 18, 2026 |
All 560 Celularity Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.